In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

(RTTNews) - Merck & Co. Inc. (MRK) said Tuesday that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...